Allergan Zymar approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan's fourth generation fluoroquinolone Zymar (gatifloxacin ophthalmic solution, 0.3%) clears FDA March 28 for treatment of bacterial conjunctivitis. Allergan is touting Zymar's dual mechanism of action, which provides enhanced inhibition of both DNA-gyrase and topoisomerase IV. The firm expects to launch by the end of Apri